Cyberonics Banking On Appeals To Avoid VNS Randomized Trial Requirement
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics will defer a new randomized trial of its VNS Therapy depression indication until it can determine whether an appeal of FDA's recent not-approvable decision may be successful